Feb 04, 2026

Email 1:

Subject: What Paige Bueckers can teach doctors

Summary: This newsletter provides insights on what doctors can learn from the mindset of Paige Bueckers, a WNBA star. It highlights lessons on efficiency, teamwork, and resilience applicable in medical practice. The issue also covers important health topics, including the silent disease PAD causing over 400 amputations daily in the U.S., discussions on augmented empathy in AI healthcare, physician leadership training from medical school onward, challenges with AI study tools impacting critical thinking, the digital divide in rural health, difficulties finding physician jobs, psychiatric care crises, IVF embryo failures, and advocacy for permanent telemedicine. Physician stories, research updates, and leadership ideas are featured.

Email 2:

Subject: The peptide with big claims but limited data

Summary: This edition focuses on BPC-157, a peptide popular among wellness communities despite limited scientific evidence and safety concerns. Some users report benefits like faster healing and pain reduction, while others experience negative effects. The report traces the peptide’s rise to prominence starting from research in Croatia. Other items include a new White House initiative addressing addiction’s “spiritual malaise,” impacts of immigration enforcement on healthcare utilization, updates on measles outbreaks in ICE detention centers, research suggesting cancer immunotherapy might be more effective when administered in the morning, and the latest on HPV vaccination affecting cervical cancer screening intervals.

Email 3:

Subject: 💊 Drug price puzzles

Summary: This newsletter investigates the mystery surrounding confidential drug pricing agreements made during the Trump administration, particularly with companies like Eli Lilly and Pfizer. There is scrutiny over transparency and the actual impact on drug costs, especially for Medicaid. Additional updates cover the partial government shutdown affecting over 23,000 HHS employees and hindering key health activities such as CDC communications and NIH clinical admissions. Data reveals that nearly 60% of commercially insured patients have chronic conditions, raising healthcare costs. Lastly, proposals in Arizona to make ivermectin available over the counter are discussed amid medical opposition.

Email 4:

Subject: What people with no ‘mind’s eye’ can tell us about consciousness

Summary: This issue explores fascinating topics about the human mind and consciousness, including the return of cursive handwriting in schools and its debated cognitive benefits, updates to psychiatric diagnostic manuals to include sociocultural factors and dimensionality of disorders, and innovative brain-computer interfaces using ultrasound aiming to treat mental conditions non-invasively. A feature article delves into aphantasia—the inability to visualize mental images—and its implications for understanding consciousness, emotions, and creativity. There are also discussions on advancing the stalled Global Plastics Treaty with procedural reforms and a video showcasing a versatile six-finger robot designed for challenging environments.

Email 5:

Subject: Hey there – Here’s what you missed in January 👀

Summary: This newsletter recaps leading health and science stories from January. Highlights include sweeping FDA changes to regulation of wearables and AI devices, breakthroughs in AI-designed drug-like antibodies poised to transform biopharma, a biotech Q1 scorecard with key stock-moving events, revelations of financial ties between dietary guideline panel members and the meat/dairy industries, and significant fundraising for AI biotech founded by former Google CEO Eric Schmidt. Additional coverage touches on new durable eye treatments, political challenges facing the FDA, perspectives on Trump’s drug pricing policy and gene therapy from Regeneron’s chief scientist, and insights shared by health officials at JPM 2026.

Stay Well!